AETHLON MEDICAL, INC.
Moat Score — Aethlon Medical, Inc.
Total Moat Score
4 / 30
| Moat Factor | Score | Analysis |
|---|---|---|
| Intangible Assets Patents, trademarks, brand strength, or regulatory licenses that protect a company's products or services from being freely copied by competitors. | 2 / 5 | Aethlon holds patents around its affinity-based Hemopurifier filtration technology, a genuinely distinctive mechanism with limited direct device competitors, though it has not yet been validated through regulatory approval or broad clinical adoption. |
| Cost Advantage A durable ability to produce goods or services more cheaply than competitors — through scale, unique access to cheap inputs, location, or process — that lets a company undercut rivals or out-earn them at the same price. | 0 / 5 | As a pre-revenue clinical-stage device company, Aethlon has no manufacturing scale or cost advantage and is a net cash consumer funded through equity raises and occasional grants. |
| Pricing Power The ability to raise prices without losing meaningful business, because the product or service is differentiated, mission-critical, or has few good substitutes. | 0 / 5 | With no commercialized product, Aethlon has no pricing power today; future pricing would depend on demonstrated clinical benefit and payer acceptance of a novel extracorporeal device used alongside existing cancer or antiviral treatments. |
| Network Effect The product or service becomes more valuable to every user as more people or organizations use it, making an established leader harder to displace. | 0 / 5 | There is no network effect in an extracorporeal blood-filtration device business. |
| Switching Costs The money, time, or operational disruption a customer would face switching to a competitor, which locks in existing customers and supports renewals. | 1 / 5 | Because the Hemopurifier is intended as a combination therapy alongside existing immunotherapy or antiviral treatment rather than a replacement, there is little incumbent technology to switch away from, though this also means Aethlon must create new treatment-protocol adoption rather than displace an established competitor. |
| Efficient Scale A market that can only profitably support a small number of players, so incumbents face limited threat from new entrants even without other defenses. | 1 / 5 | Aethlon operates in a narrow, largely uncontested device niche (affinity-based exosome/virus filtration), which could support efficient scale for a focused player if clinically validated, but this remains hypothetical pre-approval. |